BR0100878A - Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz - Google Patents

Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz

Info

Publication number
BR0100878A
BR0100878A BR0100878-1A BR0100878A BR0100878A BR 0100878 A BR0100878 A BR 0100878A BR 0100878 A BR0100878 A BR 0100878A BR 0100878 A BR0100878 A BR 0100878A
Authority
BR
Brazil
Prior art keywords
compounds
imidazolidine
oxo
carboxylic acid
matrix metalloproteinases
Prior art date
Application number
BR0100878-1A
Other languages
English (en)
Inventor
Ellen Ruth Laird
Ralph Pelton Robinson Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0100878A publication Critical patent/BR0100878A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)

Abstract

Patente de Invenção: "COMPOSTOS DE HIDROXAMIDAS DOáCIDO 2-OXO-IMIDAZOLIDINO-4-CARBOXìLICO QUE INIBEMMETALOPROTEINASES DE MATRIZ". A presente invençãorefere-se a um composto de fórmula em que R^ 1^, R^ 2^, R^ 3^ eR^ 4^ são como definidos acima, e os seus sais e solvatosfarmaceuticamente aceitáveis, que são úteis, por exemplo, comoinibidores de metaloproteinases de matriz. A presente invençãotambém é dirigida a composições farmacêuticas compreendendoesses compostos e a métodos de tratamento de doenças tais comoosteoartrite, artrite reumatóide, câncer, osteoporose, ulceração detecidos, restenose, doença peridontal, inflamação, epidermólisebulhosa, esclerite, síncope, doença de Alzheimer, e outrassemelhantes, caracterizadas por atividade inapropriada demetaloproteinases de matriz. Também são descritos processos paraa síntese de compostos de formula (I).
BR0100878-1A 2000-03-13 2001-03-12 Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz BR0100878A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18889200P 2000-03-13 2000-03-13

Publications (1)

Publication Number Publication Date
BR0100878A true BR0100878A (pt) 2001-10-30

Family

ID=22694989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0100878-1A BR0100878A (pt) 2000-03-13 2001-03-12 Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz

Country Status (10)

Country Link
US (2) US6458822B2 (pt)
EP (1) EP1134215B1 (pt)
JP (1) JP3841646B2 (pt)
AT (1) ATE278675T1 (pt)
BR (1) BR0100878A (pt)
CA (1) CA2340138C (pt)
DE (1) DE60106117T2 (pt)
DK (1) DK1134215T3 (pt)
ES (1) ES2225422T3 (pt)
PT (1) PT1134215E (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
EP1373199A4 (en) * 2001-03-15 2004-04-07 Bristol Myers Squibb Pharma Co SPIROCYCLIC BETA-AMINOACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND THE CONVERSION ENZYME OF TNF-ALPHA (TAGE)
JPWO2003080041A1 (ja) * 2002-03-27 2005-07-21 塩野義製薬株式会社 変形性関節症治療薬
CA2492035A1 (en) * 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
TW200410923A (en) * 2002-10-17 2004-07-01 Ono Pharmaceutical Co Therapeutic agent for chronic obstructive pulmonary disease
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
KR20110140139A (ko) * 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 S1p 수용체 결합능을 갖는 화합물 및 그 의약 용도
DE102004060229A1 (de) * 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
ZA966885B (en) 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
US5612074A (en) 1995-12-21 1997-03-18 Leach; Robin L. Nutrient fortified food bar
NZ333303A (en) 1996-07-18 2000-06-23 Lawrence Alan Reiter Phosphinate based inhibitors of matrix metalloproteases
BR9711223A (pt) 1996-08-23 1999-08-17 Pfizer Derivados de cido arilsulfonilamino-hidrox mico
AU731319B2 (en) 1996-08-28 2001-03-29 Procter & Gamble Company, The Heterocyclic metalloprotease inhibitors
ATE226193T1 (de) 1996-08-28 2002-11-15 Procter & Gamble Substituierte zyklische amine als metalloproteaseinhibitoren
HUP0000657A3 (en) 1997-02-11 2000-10-30 Pfizer N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用
GT199900044A (es) 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
AU4692399A (en) 1998-06-17 2000-01-05 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
ES2242402T3 (es) 1998-08-12 2005-11-01 Pfizer Products Inc. Inhibidores de tace.
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives

Also Published As

Publication number Publication date
CA2340138C (en) 2005-10-18
DK1134215T3 (da) 2005-01-10
ES2225422T3 (es) 2005-03-16
PT1134215E (pt) 2004-12-31
US6458822B2 (en) 2002-10-01
US20010041710A1 (en) 2001-11-15
EP1134215B1 (en) 2004-10-06
JP3841646B2 (ja) 2006-11-01
US20020147224A1 (en) 2002-10-10
JP2001261656A (ja) 2001-09-26
DE60106117D1 (de) 2004-11-11
EP1134215A1 (en) 2001-09-19
DE60106117T2 (de) 2005-10-13
ATE278675T1 (de) 2004-10-15
CA2340138A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
BR0100878A (pt) Compostos de hidroxamidas do ácido2-oxo-imidazolidino-4-carboxìlico que inibemmetaloproteinases de matriz
DE69939752D1 (de) 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors
IT1314184B1 (it) Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
DE69813571D1 (de) 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
ATE208397T1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
NO20024042D0 (no) Aryl-fusjonerte azapolysykliske forbindelser
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
NZ325559A (en) Metalloproteinase inhibitors, pharmaceutical compoMetalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical usitions containing them and their pharmaceutical uses, and methods and intermediates useful for theises, and methods and intermediates useful for their preparation r preparation
DK0898562T3 (da) Hydroxamsyrederivater til anvendelse ved behandling af sygdomme relateret til bindevævsdegenerering
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
EA200801261A1 (ru) Фармацевтические композиции на основе галлия и способы
ATE509905T1 (de) Benzamidderivate
TW363056B (en) Inhibition of matrix metalloproteases by substituted phenethyl compounds
CA2392271A1 (en) Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
DK1179342T3 (da) Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse
NO20032314L (no) Nye desloratadinsalter, fremgangsmåte for deres syntese og farmasöytiske preparater derav
AU2002254124A1 (en) Aryl-n-cyanoguanidines and methods related thereto
EP1386608A4 (en) MEANS FOR THE TREATMENT OF GLOMERULOPATHY
WO2003053331A3 (en) Protease inhibitors
JP3919844B2 (ja) エポキシコハク酸誘導体
MA30882B1 (fr) Derives d'acides vinylogues en tant qu'inhibiteur de la chymase
MY133525A (en) Ethyl(2s)-2-(naphthalene-1-sulfonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionate hemifumarate, a process and intermediates for its preparation, and its use asa pharmaceutical
TH62460A (th) ตัวยับยั้งเมทัลโลโพรทีเอสที่ได้รับการแทนที่ที่ n ซึ่งมีโซ่ข้างเฮเทอโรไซคลิค

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.